Search details
1.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med
; 65(5): 708-713, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38575192
Results
1 -
1
de 1
1
Next >
>>